Massachusetts Financial Services Co. MA increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 688,228 shares of the biopharmaceutical company’s stock after acquiring an additional 15,831 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.55% of Alnylam Pharmaceuticals worth $121,885,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after purchasing an additional 126,373 shares in the last quarter. BlackRock Inc. grew its holdings in Alnylam Pharmaceuticals by 0.7% during the 1st quarter. BlackRock Inc. now owns 8,548,962 shares of the biopharmaceutical company’s stock valued at $1,712,528,000 after buying an additional 59,582 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Alnylam Pharmaceuticals by 0.3% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,202,793 shares of the biopharmaceutical company’s stock worth $761,144,000 after buying an additional 10,609 shares in the last quarter. State Street Corp raised its holdings in shares of Alnylam Pharmaceuticals by 2.1% in the first quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock worth $475,091,000 after acquiring an additional 59,101 shares during the last quarter. Finally, Capital International Investors lifted its position in shares of Alnylam Pharmaceuticals by 29.2% in the second quarter. Capital International Investors now owns 2,880,643 shares of the biopharmaceutical company’s stock valued at $547,152,000 after acquiring an additional 651,054 shares in the last quarter. Institutional investors and hedge funds own 93.98% of the company’s stock.
Alnylam Pharmaceuticals Trading Down 2.1 %
ALNY stock opened at $168.60 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $148.10 and a twelve month high of $227.91. The company has a market capitalization of $21.16 billion, a P/E ratio of -40.72 and a beta of 0.43. The firm has a 50 day simple moving average of $183.74 and a 200-day simple moving average of $179.92.
Insider Transactions at Alnylam Pharmaceuticals
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. Royal Bank of Canada cut their target price on shares of Alnylam Pharmaceuticals from $235.00 to $230.00 and set an “outperform” rating for the company in a research note on Friday, November 3rd. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. HC Wainwright reaffirmed a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, December 15th. Oppenheimer downgraded Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 11th. Finally, Piper Sandler raised their price objective on Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the stock an “overweight” rating in a report on Thursday, December 14th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $230.95.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- UiPath’s AI bots can trigger its tipping point in 2024
- How to Invest and Trade Chinese Stocks
- Why Cigna stock will be at fresh highs by March
- Large Cap Stock Definition and How to Invest
- How to use options to collect rent on stocks without owning them
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.